Genentech Builds Tarceva Inventory Following Iressa's Failed Trial
This article was originally published in The Pink Sheet Daily
Executive Summary
Genentech has been building inventory for its non-small cell lung cancer agent Tarceva (erlotinib) following AstraZeneca's announcement that Iressa (gefitinib) failed to show a statistically significant survival benefit